This transcript has been edited for clarity.
The American Diabetes Association (ADA) 2021 Standards of Care have just been released, and I'm going to discuss the key changes that I think are important. I will go through some of the sections and highlight the differences from the prior year's standards of care.
Section 1: Improving Care and Promoting Health in Populations
In Section 1, we focus on the notion of understanding the social determinants of health for an individual patient. I encourage you to look at the scientific review that was recently published discussing social determinants of health in people with diabetes.
Section 2: Classification and Diagnosis of Diabetes
The big difference in Section 2, at least in my mind, is that we now include latent autoimmune diabetes in adults (LADA). "LADA" is kind of an oddball term because it's very commonly used in the general population. A lot of patients say they have LADA, but we have not really defined it.
The key to LADA is that it's really an awareness that the patient is having an autoimmune beta-cell destructive process. This can occur in adults and appears to be different than the process in children. Adults can have a very long duration of marginal
Pediatric Type 1 Diabetes Mellitus
COMMENTARY
Key Changes to the 2021 ADA Standards of Care
Anne L. Peters, MD
DisclosuresJanuary 04, 2021
This transcript has been edited for clarity.
The American Diabetes Association (ADA) 2021 Standards of Care have just been released, and I'm going to discuss the key changes that I think are important. I will go through some of the sections and highlight the differences from the prior year's standards of care.
Section 1: Improving Care and Promoting Health in Populations
In Section 1, we focus on the notion of understanding the social determinants of health for an individual patient. I encourage you to look at the scientific review that was recently published discussing social determinants of health in people with diabetes.
Section 2: Classification and Diagnosis of Diabetes
The big difference in Section 2, at least in my mind, is that we now include latent autoimmune diabetes in adults (LADA). "LADA" is kind of an oddball term because it's very commonly used in the general population. A lot of patients say they have LADA, but we have not really defined it.
The key to LADA is that it's really an awareness that the patient is having an autoimmune beta-cell destructive process. This can occur in adults and appears to be different than the process in children. Adults can have a very long duration of marginal
Medscape Diabetes © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Anne L. Peters. Key Changes to the 2021 ADA Standards of Care - Medscape - Jan 04, 2021.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Anne L. Peters, MD
Professor, Department of Clinical Medicine, Keck School of Medicine; Director, University of Southern California Westside Center for Diabetes, University of Southern California, Los Angeles, California
Disclosure: Anne L. Peters, MD, has disclosed the following relevant financial relationships:
Serve(d) on the advisory board for: Abbott Diabetes Care; Becton Dickinson; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Lexicon Pharmaceuticals, Inc.; Livongo; Medscape; Merck & Co., Inc.; Novo Nordisk; Omada Health; OptumHealth; sanofi; Zafgen
Received research support from: Dexcom; MannKind Corporation; Astra Zeneca
Serve(d) as a member of a speakers bureau for: Novo Nordisk